药易购(300937) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was ¥910,012,727.88, representing a 9.52% increase compared to ¥830,916,487.56 in the same period last year[3] - Net profit attributable to shareholders reached ¥9,136,693.85, a significant increase of 746.52% from ¥1,079,321.55 in the previous year[3] - The net profit after deducting non-recurring gains and losses was ¥6,798,768.20, up 346.31% from a loss of ¥2,760,263.93 in the same period last year[3] - Basic and diluted earnings per share were both ¥0.10, reflecting a 900.00% increase from ¥0.01 in the previous year[3] - Total operating revenue for Q1 2022 reached CNY 910,012,727.88, an increase of 9.6% compared to CNY 830,916,487.56 in Q1 2021[19] - Net profit for Q1 2022 was CNY 7,414,416.55, significantly higher than CNY 1,293,861.48 in Q1 2021, marking a growth of 473.5%[20] - Earnings per share for Q1 2022 were CNY 0.10, compared to CNY 0.01 in Q1 2021, indicating a tenfold increase[21] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,322,687,904.54, an increase of 11.42% from ¥1,187,068,605.90 at the end of the previous year[3] - The total current assets increased to CNY 970,341,153.26 from CNY 831,684,671.94, representing a growth of approximately 16.7%[15] - Total liabilities increased to CNY 512,089,643.24 in Q1 2022 from CNY 399,131,979.12 in Q1 2021, reflecting a growth of 28.3%[17] - The total non-current assets decreased slightly to CNY 261,626,110.12 from CNY 261,953,000.00, a marginal decline of about 0.1%[15] Cash Flow - The net cash flow from operating activities improved to -¥57,440,183.26, a 45.90% improvement from -¥106,177,249.12 in the same period last year[3] - The company's cash flow from operating activities for Q1 2022 was CNY 628,484,597.81, compared to CNY 547,910,269.81 in Q1 2021, showing an increase of 14.7%[23] - Total cash inflow from operating activities amounted to 643,727,865.40 CNY, compared to 555,287,111.76 CNY in the same period last year, reflecting a year-over-year increase of approximately 15.9%[24] - Cash outflow from operating activities totaled 701,168,048.66 CNY, up from 661,464,360.88 CNY, indicating a rise of about 6.5%[24] - The net cash flow from investing activities was 6,417,422.29 CNY, a significant recovery from -9,189,364.05 CNY in the previous year[24] - The ending cash and cash equivalents balance was 89,292,730.22 CNY, down from 214,465,761.82 CNY, reflecting a decrease of about 58.4%[25] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 15,413[8] - The largest shareholder, Li Yanfei, holds 36.97% of the shares, totaling 35,370,000 shares[9] Future Outlook - The company plans to release new products and technologies in the upcoming quarters, focusing on market expansion strategies[12] - The company is also exploring potential mergers and acquisitions to enhance its market position and product offerings[12] - Future performance guidance remains optimistic, with expectations of continued growth in user data and market share[12] Research and Development - The company received government subsidies amounting to ¥2,629,363.94, related to R&D and other operational support[5] - Research and development expenses for Q1 2022 were CNY 4,976,547.82, indicating ongoing investment in innovation[19]